J Randolph Hecht Selected Research

Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

6/2015	SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
6/2008	Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
6/2005	Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J Randolph Hecht Research Topics

Disease

30	Colorectal Neoplasms (Colorectal Cancer) 08/2023 - 04/2002
24	Neoplasms (Cancer) 03/2024 - 02/2003
14	Adenocarcinoma 06/2023 - 02/2003
5	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 02/2003
5	Colonic Neoplasms (Colon Cancer) 01/2021 - 11/2004
4	Diarrhea 02/2016 - 04/2002
4	Disease Progression 06/2015 - 03/2007
3	Carcinoma (Carcinomatosis) 01/2023 - 04/2002
3	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2003
3	Neutropenia 06/2015 - 04/2010
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 11/2017
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022 - 02/2008
2	Breast Neoplasms (Breast Cancer) 06/2017 - 11/2004
2	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 06/2015
2	Hypertension (High Blood Pressure) 12/2012 - 06/2005
2	Infections 04/2010 - 02/2009
2	Stomach Neoplasms (Stomach Cancer) 03/2010 - 05/2006
1	Inflammation (Inflammations) 03/2024
1	Hematologic Neoplasms (Hematological Malignancy) 06/2023
1	Lymphatic Metastasis 01/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023
1	Ovarian Neoplasms (Ovarian Cancer) 01/2023
1	Microsatellite Instability 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 07/2015
1	Dehydration (Water Stress) 06/2015
1	Hypotension (Low Blood Pressure) 06/2015
1	Hypokalemia 06/2015
1	Melanoma (Melanoma, Malignant) 01/2015
1	Hypoxia (Hypoxemia) 05/2011
1	Febrile Neutropenia 04/2010

Drug/Important Bio-Agent (IBA)

15	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 09/2007
15	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 03/2003
13	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 04/2002
12	Leucovorin (Folinic Acid)FDA Link 01/2021 - 06/2005
12	Panitumumab (Vectibix)FDA Link 08/2017 - 01/2006
11	ErbB Receptors (EGF Receptor)IBA 01/2019 - 11/2006
11	Bevacizumab (Avastin)FDA Link 08/2017 - 06/2005
7	Monoclonal AntibodiesIBA 01/2017 - 06/2005
5	Capecitabine (Xeloda)FDA Link 06/2017 - 12/2012
4	Gemcitabine FDA Link 01/2021 - 02/2003
4	Lapatinib (GW572016)FDA Link 06/2017 - 03/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2015 - 06/2005
2	IpilimumabIBA 03/2024 - 01/2022
2	Immune Checkpoint InhibitorsIBA 03/2024 - 06/2023
2	NivolumabIBA 03/2024 - 01/2022
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2015
2	pegilodecakinIBA 01/2021 - 01/2021
2	Carcinoembryonic AntigenIBA 11/2020 - 10/2017
2	Angiogenesis InhibitorsIBA 01/2019 - 05/2011
2	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2017 - 01/2017
2	Immunoglobulin G (IgG)IBA 01/2017 - 01/2017
2	simtuzumabIBA 01/2017 - 01/2017
2	Codon (Codons)IBA 09/2015 - 07/2014
2	Cetuximab (Erbitux)FDA Link 09/2015 - 03/2015
2	Epidermal Growth Factor (EGF)IBA 09/2015 - 07/2007
2	Everolimus FDA Link 07/2015 - 03/2015
2	AntibodiesIBA 06/2015 - 05/2006
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2015 - 02/2008
2	Sunitinib (Sutent)FDA Link 01/2015 - 03/2008
2	vatalanib (PTK787)IBA 05/2011 - 05/2011
2	Imatinib Mesylate (Gleevec)FDA Link 03/2008 - 02/2008
2	Cisplatin (Platino)FDA LinkGeneric 05/2006 - 04/2002
2	dl1520 (ONYX-015)IBA 04/2003 - 02/2003
1	Messenger RNA (mRNA)IBA 03/2024
1	Combined VaccinesIBA 03/2024
1	VaccinesIBA 03/2024
1	HLA Antigens (Human Leukocyte Antigens)IBA 03/2024
1	16S Ribosomal RNAIBA 01/2023
1	Temozolomide (Temodar)FDA LinkGeneric 01/2023
1	talazoparibIBA 01/2023
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2022
1	InterleukinsIBA 01/2021
1	Biosimilar PharmaceuticalsIBA 01/2021
1	gallium Ga 68 dotatateIBA 11/2017
1	labetuzumab govitecanIBA 10/2017
1	Cell Adhesion MoleculesIBA 10/2017
1	Immunoconjugates (Immunoconjugate)IBA 10/2017
1	Proton Pump InhibitorsIBA 06/2017
1	EnzymesIBA 01/2017
1	Epirubicin (Ellence)FDA LinkGeneric 01/2017
1	human ERBB2 proteinIBA 02/2016
1	talimogene laherparepvecIBA 01/2015
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2015
1	Indicators and Reagents (Reagents)IBA 10/2014
1	XELOXIBA 12/2012
1	Lactate Dehydrogenase 5IBA 05/2011
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 05/2011
1	pegfilgrastim (Neulasta)FDA Link 04/2010
1	Proteins (Proteins, Gene)FDA Link 03/2010
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2010

Therapy/Procedure

19	Therapeutics 08/2023 - 02/2003
16	Drug Therapy (Chemotherapy) 01/2023 - 04/2003
2	Immunotherapy 06/2023 - 01/2015
2	Radiotherapy 10/2022 - 02/2012
1	Neoadjuvant Therapy 10/2022
1	Lymph Node Excision (Lymph Node Dissection) 01/2022
1	Adjuvant Chemotherapy 12/2012
1	Cutaneous Administration 02/2012
1	Chemoradiotherapy 02/2012